Europe Medicine Agency (EMA)

Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First ever Marketing Authorization by European Commission for both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine

adminMay 2, 20220839 views

Summary : Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing…

Myovant Sciences Announces European Commission Approval for ORGOVYX® (Relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

adminMay 2, 20220709 views

Summary : ORGOVYX® is the first and only oral and rogend privation therapy for advanced hormone-sensitive prostate cancerin Europe Myovant expects to secure European…

EMA establishes a Cancer Medicines Forum to optimize Cancer Treatments in Clinical practice

adminApril 4, 20220592 views

Summary EMA has launched the Cancer Medicines Forum (CMF) in collaboration with the European Organization for Research and Treatment of Cancer (EORTC).…

EMA: Human medicines highlights of 2021

adminFebruary 19, 20220864 views

In 2021, EMA recommended 92 medicines for marketing authorisation. Of these, 53 had a new active substance which had never been authorised…